Mar 20, 2019

FDA approves first postpartum depression drug

Food and Drug Administration headquarters in White Oak, Md. Photo: Al Drago/CQ Roll Call

The U.S. Food and Drug Administration on Tuesday approved the first-ever drug for the treatment of postpartum depression.

Why it matters: The injectable drug, to be called Zulresso, offers new hope for mothers who experience symptoms of postpartum depression after pregnancy, including feelings of sadness and anxiety that might interfere with their ability to provide their babies with care. The symptoms can be severe and even life threatening.

Details: The drug is administered as a continuous IV infusion over a total of 60 hours, per the FDA. Patients, who must remain at a certified medical center during treatment, may experience side effects, such as headache, dizziness or excessive sleepiness.

Sage Therapeutics, the company that developed the drug, confirmed to CNN that the infusion will cost between $20,000 and $30,000. It's expected to be available by late June.

Our thought bubble: As Axios' Eileen Drage O'Reilly explains, this remedy is greatly needed. But low-income women (who are more susceptible to postpartum depression) and those who lack adequate insurance coverage, are largely unable to afford both the treatment and meet the requirement to be overnight in a hospital or clinical setting for a 60-hour infusion. So, it's not exactly accessible to most people. But, it's a start.

Go deeper

New Zealand sets sights on coronavirus elimination after 2 weeks of lockdown

Prime Minister Jacinda Ardern gives a coronavirus media update at the New Zealand Parliament in Wellington. Photo: Mark Mitchell - Pool/Getty Images

AUCKLAND -- New Zealand has flattened the curve of novel coronavirus cases after two weeks of lockdown and the next phase is to "squash it," Professor Shaun Hendy, who heads a body advising the government on COVID-19, told Axios.

Why it matters: The country imposed 14 days ago some of the toughest restrictions in the world in response to the pandemic, despite confirming only 102 cases and no deaths at the time.

Go deeperArrow19 mins ago - Health

Coronavirus dashboard

Illustration: Sarah Grillo/Axios

  1. Global: Total confirmed cases as of 2:30 a.m. ET: 1,431,375 — Total deaths: 82,145 — Total recoveries: 301,543Map.
  2. U.S.: Total confirmed cases as of 2:30 a.m. ET: 399,886 — Total deaths: 12,910 — Total recoveries: 22,461Map.
  3. Federal government latest: Acting Navy secretary resigns over handling of virus-infected ship — Trump removes watchdog overseeing rollout of $2 trillion coronavirus bill — Trump said he "didn't see" memos from his trade adviser Peter Navarro warning that the crisis could kill more than half a million Americans.
  4. States latest: California Gov. Gavin Newsom is confident that more than 200 million masks will be delivered to the state "at a monthly basis starting in the next few weeks."
  5. Business latest: America's food heroes in times of the coronavirus crisis. Even when the economy comes back to life, huge questions for airlines will remain.
  6. World updates: China reopens Wuhan after 10-week coronavirus lockdown.
  7. 2020 latest: Polls for Wisconsin's primary elections closed at 9 p.m. ET Tuesday, but results won't be released until April 13. Thousands of residents cast ballots in person.
  8. 1 Olympics thing: About 6,500 athletes who qualified for the Tokyo Games will keep their spots in 2021.
  9. What should I do? Pets, moving and personal healthAnswers about the virus from Axios expertsWhat to know about social distancingQ&A: Minimizing your coronavirus risk.
  10. Other resources: CDC on how to avoid the virus, what to do if you get it.

Subscribe to Mike Allen's Axios AM to follow our coronavirus coverage each morning from your inbox.

Tariff worries hit record high amid coronavirus outbreak

Data: CivicScience, margin of error ±1 percentage points; Chart: Axios Visuals

Concern about President Trump's tariffs on U.S imports grew to record high levels among Americans last month, particularly as more lost their jobs and concern about the novel coronavirus increased.

Driving the news: About seven in 10 people said they were at least somewhat concerned about tariffs in March, according to the latest survey from CivicScience provided first to Axios.